SG10201706937UA - Compositions for Use in Treating Eye Disorders Using Dipyridamole - Google Patents

Compositions for Use in Treating Eye Disorders Using Dipyridamole

Info

Publication number
SG10201706937UA
SG10201706937UA SG10201706937UA SG10201706937UA SG10201706937UA SG 10201706937U A SG10201706937U A SG 10201706937UA SG 10201706937U A SG10201706937U A SG 10201706937UA SG 10201706937U A SG10201706937U A SG 10201706937UA SG 10201706937U A SG10201706937U A SG 10201706937UA
Authority
SG
Singapore
Prior art keywords
dipyridamole
compositions
eye disorders
treating eye
treating
Prior art date
Application number
SG10201706937UA
Other languages
English (en)
Inventor
Rogosnitzky Moshe
Original Assignee
O D Ocular Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by O D Ocular Discovery Ltd filed Critical O D Ocular Discovery Ltd
Publication of SG10201706937UA publication Critical patent/SG10201706937UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG10201706937UA 2013-03-12 2014-03-11 Compositions for Use in Treating Eye Disorders Using Dipyridamole SG10201706937UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL225179A IL225179A (en) 2013-03-12 2013-03-12 Compounds for use in ocular disorders using dipyridamole

Publications (1)

Publication Number Publication Date
SG10201706937UA true SG10201706937UA (en) 2017-09-28

Family

ID=48916407

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201507092QA SG11201507092QA (en) 2013-03-12 2014-03-11 Compositions for use in treating eye disorders using dipyridamole
SG10201706937UA SG10201706937UA (en) 2013-03-12 2014-03-11 Compositions for Use in Treating Eye Disorders Using Dipyridamole

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201507092QA SG11201507092QA (en) 2013-03-12 2014-03-11 Compositions for use in treating eye disorders using dipyridamole

Country Status (14)

Country Link
EP (1) EP2968328A4 (fr)
JP (1) JP6820658B2 (fr)
KR (2) KR20210010638A (fr)
CN (1) CN105188702B (fr)
AU (1) AU2014229371B2 (fr)
BR (1) BR112015022084A2 (fr)
CA (1) CA2905594A1 (fr)
CL (1) CL2015002627A1 (fr)
EA (1) EA035966B1 (fr)
IL (1) IL225179A (fr)
MX (1) MX2015012716A (fr)
MY (1) MY182591A (fr)
SG (2) SG11201507092QA (fr)
WO (1) WO2014141079A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180015090A1 (en) * 2015-01-28 2018-01-18 Realinn Life Science Limited COMPOUNDS FOR ENHANCING PPARy EXPRESSION AND NUCLEAR TRANSLOCATION AND THERAPEUTIC USE THEREOF
US20180092776A1 (en) 2016-09-30 2018-04-05 Sara Heikali Method and device for treating and managing diseased ocular tissue
WO2021001806A1 (fr) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Formulations de dipyridamole stables avec des impuretés réduites
WO2021001805A1 (fr) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Formulations de dipyridamole stables et leurs procédés de préparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258084A (ja) * 1994-03-17 1995-10-09 Rohto Pharmaceut Co Ltd ジピリダモールを必須成分とする眼圧降下剤
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
RU2008122978A (ru) * 2005-11-09 2009-12-20 Комбинаторкс, Инкорпорейтед (Us) Способы, композиции и наборы для лечения медицинских состояний
WO2010056710A1 (fr) * 2008-11-11 2010-05-20 Biovista, Inc. Compositions et procédés pour traiter des maladies ophtalmiques
EP2363126A1 (fr) * 2010-03-04 2011-09-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composition comprenant une L-carnitine en tant que principe actif en combinaison avec le glucoside de l'hydroxykynurénine, pour la prévention et/ou le traitement de pathologies de l'oeil dues au rayonnement ultraviolet

Also Published As

Publication number Publication date
CL2015002627A1 (es) 2016-03-11
KR20150126021A (ko) 2015-11-10
IL225179A0 (en) 2013-06-27
MX2015012716A (es) 2016-07-06
MY182591A (en) 2021-01-26
CA2905594A1 (fr) 2014-09-18
KR20210010638A (ko) 2021-01-27
SG11201507092QA (en) 2015-10-29
IL225179A (en) 2017-01-31
EA035966B1 (ru) 2020-09-07
WO2014141079A1 (fr) 2014-09-18
EP2968328A4 (fr) 2016-11-23
EP2968328A1 (fr) 2016-01-20
AU2014229371B2 (en) 2018-05-10
BR112015022084A2 (pt) 2017-07-18
JP2016514123A (ja) 2016-05-19
AU2014229371A1 (en) 2015-10-29
JP6820658B2 (ja) 2021-01-27
EA201591653A1 (ru) 2017-05-31
CN105188702B (zh) 2019-03-26
CN105188702A (zh) 2015-12-23

Similar Documents

Publication Publication Date Title
HK1225305A1 (zh) 治療腦疾病的方法和組合物
HUE061618T2 (hu) Vegyület szemrendellenességek kezelésére
HK1203830A1 (en) Compositions and methods for treating metabolic disorders
PT3882250T (pt) Tetrahidropiranil amino-pirrolopirimidinona e métodos de utilização da mesma
HK1217650A1 (zh) 用於治療劇痛的組合物及方法
EP2989123A4 (fr) Méthodes et compositions pour traiter les troubles de la coagulation
PL3041831T3 (pl) Postacie soli alfa-TEA: kompozycje i zastosowania do leczenia choroby
SG11201510300RA (en) Compositions and methods for treating skin
EP2968452A4 (fr) Compositions et procédés pour traiter une maladie rétinienne
IL242584B (en) An immunogenic preparation for use in treatment
SG10201706937UA (en) Compositions for Use in Treating Eye Disorders Using Dipyridamole
IL311363A (en) Preparations for use in the treatment of cognitive impairment
EP2978452A4 (fr) Compositions et méthodes de traitement de troubles osseux ostéolytiques
GB201308753D0 (en) Compounds and their use in therapy
IL238363A0 (en) Methods for treating eye diseases
SI2815740T1 (sl) Oftalmični sestavek
ZA201508585B (en) Immunogenic composition for use in therapy
GB201304675D0 (en) Novel compositions having use in therapy
GB201314623D0 (en) Novel mucinase for use in therapy or prophylaxis
GB201223371D0 (en) Novel mucinase for use in therapy or prophylaxis
GB201308217D0 (en) Compounds and their use in therapy